- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals - - Additional preclinical data demonstrate INDUKINETM molecules’ anti-tumor potency with distinct immune activation profiles across four cytokines - WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) --  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneerin ...

Core Insights - Indaptus Therapeutics presented promising safety, pharmacokinetics, and biomarker data for its lead compound Decoy20 at the SITC 2024 annual meeting, based on a Phase 1 clinical trial involving 19 patients [1][2][3] - The trial results indicated that Decoy20, administered intravenously once weekly, primarily resulted in mild to moderate and transient side effects, with a rapid elimination from the bloodstream supporting the company's "pulse" approach [2][3] - One patient with squamous cell carcinoma of the head and neck exhibited "stable disease" at the first imaging scan, indicating no progression of cancer [2] Company Overview - Indaptus Therapeutics focuses on innovative cancer and viral infection treatments, leveraging a patented Decoy platform that activates both innate and adaptive immune responses [4] - The Decoy technology utilizes non-pathogenic Gram-negative bacteria to stimulate immune pathways, aiming for reduced intravenous toxicity while maintaining efficacy [4] - Preclinical studies have shown Decoy candidates' effectiveness against various cancers and chronic viral infections, demonstrating potential for combination therapies with existing treatments [4] Future Directions - The company is expanding its clinical trial to include patients with six different tumor types for weekly dosing and is collaborating with BeiGene to combine Decoy20 with its PD-1 inhibitor, tislelizumab [3] - Management expresses confidence in the Decoy platform's potential and plans to continue sharing positive results while exploring new opportunities [3]

Core Insights - Oncotelic Therapeutics, Inc. presented its research at SITC 2024, focusing on the TGFB2 therapeutics pipeline [1] - Dr. Cynthia Lee, VP of R&D, has been instrumental in leading R&D programs and the establishment of a GMP facility in San Diego [1] Research Presentations - Abstract Number 198 discusses the interaction of TGFB2 mRNA levels with Interferon-alpha receptor activation and its impact on overall survival in pancreatic ductal adenocarcinoma (PDAC) [1] - Abstract Number 218 evaluates the prognostic impact of TGFB2 mRNA levels in low-grade gliomas, in conjunction with Interferon-gamma receptor activation [1] - Abstract Number 1444 presents a meta-analysis comparing serious adverse events and survival outcomes in PDAC patients treated with mFOLFIRINOX or FOLFIRINOX [1] Company Overview - Oncotelic has a rare pediatric designation for Diffuse Intrinsic Pontine Glioma (DIPG) through its joint venture, GMP Biotechnology Limited, and is involved in treatments for melanoma and Acute Myeloid Leukemia [2] - The company acquired PointR Data Inc. in November 2019 to enhance its AI-driven biotechnology capabilities [2] - Oncotelic is developing AL-101 for various conditions, including Parkinson's Disease and sexual disorders, addressing a significant patient population [2] - The first-in-class TGFB2 therapeutic for pancreatic cancer and glioblastoma is being developed through its joint venture, Sapu Bio [2]

Core Insights - Anixa Biosciences, Inc. is set to present additional data from its Phase 1 clinical trial of a breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting on November 8, 2024 [1][2] - The vaccine targets the α-lactalbumin protein, which is present in certain breast cancers but absent in normal aging tissues post-lactation, aiming to activate the immune system for preemptive protection against breast tumors [3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program and various cancer vaccines developed in collaboration with Cleveland Clinic [7] - The breast cancer vaccine technology was developed by Dr. Vincent Tuohy at Cleveland Clinic, and Anixa holds the exclusive worldwide license for this technology [5][6] Clinical Trial Details - The Phase 1 trial is conducted in collaboration with Cleveland Clinic and funded by a grant from the U.S. Department of Defense, with initial data showing no safety concerns and immune responses in a majority of patients [4][5] - The upcoming presentation will provide further analysis of the trial data, which was initially presented at the San Antonio Breast Cancer Symposium in December 2023 [4][2]

MINNEAPOLIS, Nov. 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its market-leading portfolio to advance cancer research from target discovery to personalized medicine and cell therapy development at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.Bio-Techne's spatial biology brands, Advanced Cell Diagnostics (ACD) and Lunaphore, are revolutionizing spatial biology research with their pion ...

Core Insights - Candel Therapeutics announced preclinical results demonstrating the potent antitumor activity of CAN-3110 in melanoma models, suggesting potential for indication expansion beyond high-grade glioma [1][4] - CAN-3110 is a first-in-class oncolytic viral immunotherapy designed to target Nestin-expressing cancer cells, showing dual activity for oncolysis and immune activation [2][6] - The data presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting indicates significant tumor-specific cytotoxicity and systemic immune activation in melanoma models [4][5] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer treatment [7] - The company has established two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs [7] - CAN-3110 is currently in a phase 1b clinical trial for recurrent high-grade glioma, with previous results indicating improved median overall survival compared to historical controls [6][7] Research Findings - The poster presentation titled "Therapeutic potential of CAN-3110 in Ras-Raf pathway altered melanoma" highlights the mechanism of action and antitumor activity of CAN-3110 in preclinical melanoma models [3] - Preclinical data showed dose-dependent inhibition of tumor growth and tumor regression in melanoma-bearing mice treated with CAN-3110 [4] - The treatment was well-tolerated in animal models, with no dose-limiting toxicity reported [6]

Poster presentation at SITC to highlight extended follow-up data from AMPLIFY-7P Phase 1 study Oral presentation at SU2C Innovation Summit to highlight data from AMPLIFY-7P and AMPLIFY-201 Phase 1 studies BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced two upcoming presentations in November. The first presen ...

Core Insights - SITE Centers Corp. reported a revenue of $89.43 million for the quarter ended September 2024, reflecting a 37.5% decrease year-over-year and a surprise of -12.17% compared to the Zacks Consensus Estimate of $101.82 million [1] - The company's EPS for the quarter was $0.81, down from $0.88 in the same quarter last year, with an EPS surprise of -6.90% against the consensus estimate of $0.87 [1] Revenue Breakdown - Rental income was reported at $89.02 million, significantly lower than the three-analyst average estimate of $99.75 million, marking a year-over-year decline of 37.5% [3] - Lease termination fees amounted to $0.58 million, exceeding the average estimate of $0.20 million by two analysts, representing a substantial increase of 165.1% compared to the previous year [3] - Ancillary and other rental income was reported at $0.92 million, below the average estimate of $1.09 million, indicating a year-over-year decrease of 39.3% [3] - Percentage and overage rent revenue was $1.06 million, slightly above the average estimate of $1.03 million [3] - Recoveries totaled $22.13 million, falling short of the average estimate of $25.58 million [3] Stock Performance - Over the past month, SITE Centers Corp. shares have returned +0.3%, underperforming the Zacks S&P 500 composite's +1.8% change [4] - The stock currently holds a Zacks Rank 5 (Strong Sell), suggesting potential underperformance relative to the broader market in the near term [4]

Financial Performance - SITE Centers Corp. reported quarterly funds from operations (FFO) of $0.81 per share, missing the Zacks Consensus Estimate of $0.87 per share, and down from $1.32 per share a year ago, representing an FFO surprise of -6.90% [1] - The company posted revenues of $89.43 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 12.17%, compared to year-ago revenues of $143.09 million [2] - Over the last four quarters, the company has surpassed consensus FFO estimates two times and topped consensus revenue estimates just once [2] Stock Performance - SITE Centers Corp. shares have lost about 68.6% since the beginning of the year, while the S&P 500 has gained 22.3% [3] - The current consensus FFO estimate for the coming quarter is $0.32 on $79.29 million in revenues, and for the current fiscal year, it is $3.36 on $414.29 million in revenues [7] Industry Outlook - The REIT and Equity Trust - Retail industry is currently in the top 16% of the Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions, suggesting that investors should monitor these revisions closely [5]

Group 1 - Replimune Group, Inc. announced that a late-breaking abstract featuring the IGNYTE clinical trial primary analysis has been selected for oral presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) [1] - The ARTACUS clinical trial data of RP1 monotherapy in solid organ transplant patients with advanced cutaneous malignancies will be shared in an encore poster presentation [1] - The IGNYTE trial focuses on patients with anti-PD1 failed melanoma, presenting clinical subgroup and initial biomarker data [2] Group 2 - Replimune was founded in 2015 and aims to transform cancer treatment through novel oncolytic immunotherapies [3] - The proprietary RPx platform utilizes a potent HSV-1 backbone to maximize immunogenic cell death and induce a systemic anti-tumor immune response [3] - RPx product candidates are designed for dual local and systemic activity, allowing for synergy with established and experimental cancer treatment modalities [3]